Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + pertuzumab + trastuzumab emtansine
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination regimen of three HER2-targeted therapies used primarily in the treatment of HER2-positive breast cancer. Trastuzumab and pertuzumab are monoclonal antibodies that bind to different epitopes on the human epidermal growth factor receptor 2 (HER2), inhibiting its signaling and promoting antibody-dependent cellular cytotoxicity. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines trastuzumab with DM1, a cytotoxic agent that inhibits microtubule polymerization, thereby inducing cell death specifically in HER2-overexpressing cells. This combination has been studied for synergistic activity and improved outcomes in advanced or metastatic HER2-positive breast cancer[1][3][6].
- Brand names
- Herceptin (trastuzumab)Perjeta (pertuzumab)Kadcyla (trastuzumab emtansine)
- Other names
- ado-trastuzumab emtansinetrastuzumab-DM1trastuzumab-DM-1trastuzumab-DM 1
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on trastuzumab + pertuzumab + trastuzumab emtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + pertuzumab + trastuzumab emtansine.